Eli Lilly and Company, pharmaceutical company headquarters in Alcobendas, Madrid, Spain.
Cristina Arias | cover | Getty’s paintings
Eli LilyThe experimental drug helped patients lose up to 24% of their weight after nearly a 12 months, according to a latest study mid-phase clinical trial results released on Monday.
The phase two study involved 338 adults who were obese or chubby and received an injection from a pharmaceutical company, retatrutideor placebo every week.
Patients who took a 12-mg dose of retatrutide lost a median of 17.5% of their body weight, or 41 kilos, on average after 24 weeks, compared with 1.6% for many who took a placebo.
Patients lost a median of 24.2% or 58 kilos after 48 weeks. Those that took the placebo lost 2.1% of their body weight over the identical period.
Researchers within the study said average weight loss didn’t plateau after 48 weeks, suggesting that an extended study could show much more. Eli Lilly is currently recruiting patients for phase three trial.
These data suggest Eli Lilly’s retatrutide is “probably the most effective anti-obesity drug to date,” said Michael Weintraub, an endocrinologist at NYU Langone Health. Twitter entry.
Eli Lilly’s other obesity drug, Mounjaro, which is approved for type 2 diabetes, has helped patients lose up to 21% of their weight in clinical trials.
Novo Nordisk”s Wegovy, approved for weight loss, has showed a weight loss of up to 15%. in trials.
Like Wegovy and Mounjaro, Eli Lilly’s retatrutide is a weekly injection that changes the way in which patients eat and reduces appetite by mimicking certain hormones within the gut.
But Wegovy mimics just one hunger-regulating hormone called GLP-1, while Mounjaro mimics GLP-1 and one other hormone called GIP.
Retatrutide mimics three different hormones that regulate hunger: GLP-1, GIP, and glucagon. This seems to have a stronger effect on appetite and food satisfaction.